JAGUAR HEALTH INC (JAGX) Stock Price, Quote, News and Overview
NASDAQ:JAGX - Nasdaq - US47010C8055 - Common Stock - Currency: USD
JAGX Quote, Performance and Key Statistics
6.1
+0.47 (+8.35%)
The current stock price of JAGX is 6.1 USD. In the past month the price increased by 0.99%. In the past year, price decreased by -97.74%.
JAGX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 63.66 | 784.50B | ||
| JNJ | JOHNSON & JOHNSON | 15.7 | 380.15B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 17.37 | 265.94B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.03 | 220.04B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.35 | 210.42B | ||
| MRK | MERCK & CO. INC. | 10.34 | 198.72B | ||
| PFE | PFIZER INC | 7.24 | 127.78B | ||
| SNY | SANOFI-ADR | 11.63 | 126.93B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 43.7 | 101.37B | ||
| GSK | GSK PLC-SPON ADR | 8.46 | 74.22B | ||
| ZTS | ZOETIS INC | 25.34 | 66.90B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 33.33 | 48.25B |
Related stock screener links
About JAGX
Company Profile
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The company is headquartered in San Francisco, California and currently employs 49 full-time employees. The company went IPO on 2015-05-13. The firm is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. The company operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.
Company Info
JAGUAR HEALTH INC
200 Pine Street Suite 400
San Francisco CALIFORNIA 94104 US
CEO: Lisa A. Conte
Employees: 49
Company Website: https://jaguar.health/
Investor Relations: https://jaguarhealth.gcs-web.com/
Phone: 14153718300
JAGUAR HEALTH INC / JAGX FAQ
What is the stock price of JAGUAR HEALTH INC today?
The current stock price of JAGX is 6.1 USD. The price increased by 8.35% in the last trading session.
What is the ticker symbol for JAGUAR HEALTH INC stock?
The exchange symbol of JAGUAR HEALTH INC is JAGX and it is listed on the Nasdaq exchange.
On which exchange is JAGX stock listed?
JAGX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for JAGUAR HEALTH INC stock?
7 analysts have analysed JAGX and the average price target is 153 USD. This implies a price increase of 2408.2% is expected in the next year compared to the current price of 6.1. Check the JAGUAR HEALTH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is JAGUAR HEALTH INC worth?
JAGUAR HEALTH INC (JAGX) has a market capitalization of 4.09M USD. This makes JAGX a Nano Cap stock.
How many employees does JAGUAR HEALTH INC have?
JAGUAR HEALTH INC (JAGX) currently has 49 employees.
Is JAGUAR HEALTH INC (JAGX) expected to grow?
The Revenue of JAGUAR HEALTH INC (JAGX) is expected to grow by 40.06% in the next year. Check the estimates tab for more information on the JAGX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy JAGUAR HEALTH INC (JAGX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of JAGX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of JAGX, evaluating the profitability, health, valuation and growth aspects
- JAGUAR HEALTH INC (JAGX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- JAGUAR HEALTH INC (JAGX) Sales and EPS estimates to see what analysts future expectations are.
- JAGUAR HEALTH INC (JAGX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- JAGUAR HEALTH INC (JAGX) Insider and Institutional Ownership to learn about the owners and their transactions.
- JAGUAR HEALTH INC (JAGX) Stock Chart to make your own analysis
- JAGUAR HEALTH INC (JAGX) Latest news and press-releases to stay up to date.
Does JAGUAR HEALTH INC (JAGX) stock pay dividends?
JAGX does not pay a dividend.
When does JAGUAR HEALTH INC (JAGX) report earnings?
JAGUAR HEALTH INC (JAGX) will report earnings on 2025-05-12, before the market open.
What is the Price/Earnings (PE) ratio of JAGUAR HEALTH INC (JAGX)?
JAGUAR HEALTH INC (JAGX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-131.79).
What is the Short Interest ratio of JAGUAR HEALTH INC (JAGX) stock?
The outstanding short interest for JAGUAR HEALTH INC (JAGX) is 6.82% of its float. Check the ownership tab for more information on the JAGX short interest.
JAGX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to JAGX. When comparing the yearly performance of all stocks, JAGX is a bad performer in the overall market: 99.14% of all stocks are doing better.
JAGX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to JAGX. JAGX has a bad profitability rating. Also its financial health evaluation is rather negative.
JAGX Financial Highlights
Over the last trailing twelve months JAGX reported a non-GAAP Earnings per Share(EPS) of -131.79. The EPS increased by 74.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -72.05% | ||
| ROE | -393.98% | ||
| Debt/Equity | 2.41 |
JAGX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to JAGX. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 60.14% and a revenue growth 40.06% for JAGX